



CASE
COMPREHENSIVE
CANCER CENTER



American Association for Cancer Research (AACR)

Annual Meeting

Friday, March 29-Wednesday, April 3, 2019

(Case CCC Members in Bold)

Poster Session

172 / 19 - BCL11A regulation of extracellular matrix genes may be necessary for invasion of triple-negative breast cancer

Natasha N. Ingles, Darcie Seachrist, **Ruth Keri. Case Western Reserve University, Cleveland, OH**

Session PO.TB04.04 Genes That Regulate Migration and Invasion

March 31, 2019, 1:00 PM – 5:00 PM; Section 7

<https://www.abstractsonline.com/pp8/#!/6812/presentation/6770>

390 / 22 - Prostate cancer progression depends on the activity of the mitotic kinase citron kinase

Salma Ben-Salem¹, Salam Bachour¹, Varadha Balaji Venkadakrishnan¹, Yixue Su¹, Eduardo Cortes

Gomez², Qiang Hu², **Eric Klein¹**, Nicolas Marlo¹, **Cristina Magi-Galluzzi¹**, Liu Song², **Hannelore V.**

Heemers¹. ¹**Cleveland Clinic, Cleveland, OH**; ²Roswell Park Comprehensive Cancer Center, Buffalo, NY

Session PO.ET04.02. New Molecular Targets

March 31, 2019, 1:00PM – 5:00 PM; Section 15

<https://www.abstractsonline.com/pp8/#!/6812/presentation/2070>

686 / 19 - Quantitative analysis of the role of homologous recombination in response to radiotherapy for prostate cancer

Mengdi Qian¹, **Alexandru Almasan²**, Evren Gürkan-Çavusoglu¹. ¹**Case Western Reserve Univ., Cleveland, OH**; ²**Cleveland Clinic, Cleveland, OH**

Session PO.BSB02.01. Convergence Science for Therapeutics and Precision Medicine

March 31, 2019, 1:00 PM – 5:00 PM; Section 30

<https://www.abstractsonline.com/pp8/#!/6812/presentation/1743>

734 / 8 - Large-scale radiogenomic profiling of patient derived xenografts (PDX)

Priyanka Gopal, Titas Bera, Craig Peacock, **Mohamed Abazeed. Cleveland Clinic, Cleveland, OH**

Session PO.MCB09.01. Cancer Genomics 1

March 31, 2019, 1:00 PM – 5:00 PM; Section 33

<https://www.abstractsonline.com/pp8/#!/6812/presentation/3349>

776 / 20 - Posttranscriptional control of steroid biosynthesis pathway in prostate cancer

Asmita Bhattarai, **Girish C. Shukla. Cleveland State University, Cleveland, OH**

Session PO.MCB10.01. miRNA Regulation of Cancer Biology

March 31, 2019, 1:00 PM – 5:00 PM; Section 34

<https://www.abstractsonline.com/pp8/#!/6812/presentation/7013>

CT064 / 21 - Intranasal brain delivery using NEO100 for recurrent glioblastoma
Thomas C. Chen¹, Naveed Wagle², **David Peereboom**³, Lynne Taylor⁴. ¹USC Keck School of Medicine, La Canada Flintridge, CA; ²USC Keck School of Medicine, Los Angeles, CA; ³**Cleveland Clinic, Cleveland, OH**; ⁴University of Washington, Seattle, WA

Session PO.CT02. Phase 1 Clinical Trials: Part 2

April 1, 2019, 8:00 AM – 12:00 PM; Section 17

<https://www.abstractsonline.com/pp8/#!/6812/presentation/9879>

1171 / 20 - Identifying small molecules that specifically inhibit glioma stem cells

Anthony R. Sloan, **Raffaella Spina**, Dillon M. Voss, Sophie Laye, **Eli E. Bar. Case Western Reserve University School of Medicine, Cleveland, OH**

Session PO.TB02.03. Regulation of Cancer Stem Cell Stemness, Epithelial Mesenchymal Transition, and the Microenvironment

April 1, 2019, 8:00 AM – 12:00 PM; Section 8

<https://www.abstractsonline.com/pp8/#!/6812/presentation/1344>

1574 / 13 - Circadian clock gene expression and lethal prostate cancer outcomes

Sarah C. Mark¹, Ericka Ebot², Iona Cheng³, Lynne Wilkens⁴, Ayesha Shafi⁵, Karen Knudsen⁵, Kathryn Penney⁶, Lorelei Mucci², Travis Gerke⁷. ¹**Case Western Reserve University, Cleveland, OH**; ²Harvard T.H. Chan School of Public Health, Boston, MA; ³UCSF, San Francisco, CA; ⁴University of Hawaii, Honolulu, HI; ⁵Thomas Jefferson University, Philadelphia, PA; ⁶Channing Division of Network Medicine, Boston, MA; ⁷Moffitt Cancer Center, Tampa, FL

Session PO.EP01.08 - Genetics and Genomics 1: Outcomes

April 1, 2019, 8:00 AM - 12:00 PM; Section 26

<https://www.abstractsonline.com/pp8/#!/6812/presentation/2005>

CT123 / 22 - IMvoke010: Randomized Phase III study of atezolizumab as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)

Deborah J. Wong¹, Jerome Fayette², Ye Guo³, Matthew Kowgier⁴, Ezra Cohen⁵, Ricard Mesia Nin⁶, Arunee Dechaphunkul⁷, Kumar Prabhaskar⁸, Jessica Geiger⁹, Sarwan Bishnoi¹⁰, Henning Schafer¹¹, Christina Matheny¹², Fairouz Kabbinavar¹², Alan Sandler¹², David Raben¹³, Robert Haddad¹⁴. ¹UCLA Medical Center, Santa Monica, CA; ²Centre Léon Bérard, Lyon, France; ³Tongji University East Hospital, Shanghai, China; ⁴F. Hoffmann-La Roche, Ltd., Basel, Switzerland; ⁵University of California, San Diego, La Jolla, CA; ⁶Institut Català d'Oncologia, Gran Via de l'Hospitalet, Barcelona, Spain; ⁷Prince of Songkla University, Phuket, Thailand; ⁸Tata Memorial Hospital, Mumbai, India; ⁹**Cleveland Clinic Taussig Cancer Institute, Cleveland, OH**; ¹⁰Adelaide Cancer Center, Adelaide, Australia; ¹¹Universitätsklinikum Freiburg, Breisgau, Germany; ¹²Genentech, South San Francisco, CA; ¹³University of Colorado, Denver, CO; ¹⁴Dana-Farber Cancer Institute, Boston, MA

Session PO.CT04. Phase I-III Trials in Progress: Part 1

April 1, 2019, 1:00 PM – 5:00 PM; Section 17

<https://www.abstractsonline.com/pp8/#!/6812/presentation/9995>

2097 / 4 - LIN9 regulation of NEK2 underlies taxol resistance in triple-negative breast cancer

Melyssa S. Shively, **Ruth A. Keri. Case Western Reserve University, Cleveland, OH**

Session PO.ET03.03. Drug Resistance 3

April 1, 2019, 1:00 PM – 5:00 PM; Section 11

<https://www.abstractsonline.com/pp8/#!/6812/presentation/1614>

2505 / 1 - Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma

Nirmish Singla¹, Jacob Choi², Oreoluwa Onabolu¹, Layton Woolford¹, Christina Stevens¹, Vanina Tcheuyap¹, Tiffani McKenzie¹, Zhiqun Xie¹, Tao Wang¹, Renee McKay¹, Alana Christie¹, Payal Kapur¹, **Brian Rini**², James Brugarolas¹. ¹University of Texas Southwestern Medical Center, Dallas, TX; ²**Cleveland Clinic, Cleveland, OH**

Session PO.MCB09.04. Cancer Genomics 3

April 1, 2019, 1:00 PM – 5:00 PM; Section 33

<https://www.abstractsonline.com/pp8/#!/6812/presentation/3479>

CT172 / 16 - Phase III METIS study: Tumor Treating Fields (150 kHz) and radiosurgery for supra- and/or infratentorial brain metastases (1-10) from non-small cell lung cancer (NSCLC)

Minish P Mehta¹, Vinai Gondi², **Manmeet Ahluwalia**³, Paul D. Brown⁴. ¹Baptist Health South Florida and Miami Cancer Institute, Miami, FL; ²Northwestern Medicine Cancer Center, Warrenville, IL; ³**Cleveland Clinic, Cleveland, OH**; ⁴Mayo Clinic, Rochester, MN

Session PO.CT06. Phase I-III Trials in Progress: Part 2

April 2, 2019, 8:00 AM – 12:00 PM; Section 17

<https://www.abstractsonline.com/pp8/#!/6812/presentation/10012>

2780 / 16 - IL13RA2 is differentially regulated in papillary thyroid carcinoma versus follicular thyroid carcinoma

Siao Ting Chong¹, Catherine Y. L. Kok¹, Khee Ming Tan¹, Shou Ping Guan¹, Siang Hui Lai², Cindy Lim¹, Jiancheng Hu¹, Charles Sturgis³, **Charis Eng**⁴, Paula Y. P. Lam¹, Joanne Ngeow¹. ¹National Cancer Centre, Singapore; ²Singapore General Hospital, Singapore; ³**Cleveland Clinic, Cleveland, OH**; ⁴**Case Western Reserve University School of Medicine, Cleveland, OH**

Session PO.TB04.03. Expression Profiling and Biomarkers of Tumor Progression and Metastasis

April 2, 2019, 8:00 AM – 12:00 PM; Section 2

<https://www.abstractsonline.com/pp8/#!/6812/presentation/6721>

2897 / 4 - Dynamic transdifferentiation programs in small cell lung carcinoma

Priyanka Gopal, Kevin Rogacki, Craig D. Peacock, **Mohamed E. Abazeed**. **Cleveland Clinic, Cleveland, OH**

Session PO.TB10.01. Tumor Evolution and Heterogeneity 1

April 2, 2019, 8:00 AM – 12:00 PM; Section 7

<https://www.abstractsonline.com/pp8/#!/6812/presentation/3985>

2916 / 4 - Delineating the radiogenomic landscape of cancer through systematic annotation of genetic variants

Brian Yard, Aaron Petty, **Mohamed Abazeed**. **Cleveland Clinic, Cleveland, OH**

Session PO.TB09.01. Tumor Radiosensitivity or Resistance

April 2, 2019, 8:00 AM – 12:00 PM; Section 8

<https://www.abstractsonline.com/pp8/#!/6812/presentation/5625>

3186 / 9 - A novel combination therapy for treating advanced drug resistant acute lymphoblastic leukemia

Yorlenny M. Vicioso¹, **Rose Beck**¹, Herman Gram², Abhishek Asthana¹, Keman Zhang¹, Derek Wong¹, **John Letterio**¹, **Reshmi Parameswaran**¹. ¹Case Western Reserve University, Cleveland, OH; ²Novartis Institutes, Basel, Switzerland

Session PO.IM02.04 - Adoptive Cell Therapy 3

April 2, 2019, 8:00 AM - 12:00 PM; Section 22

<https://www.abstractsonline.com/pp8/#!/6812/presentation/2641>

3386 / 17 - Acute myeloid leukemia stem cell heterogeneity and RNA clonal expansion during disease progression and relapse

Lindsay C. Stetson¹, Dheepa Balasubramanian¹, Anne Roe¹, Susan Pereira Ribeiro¹, Xuan Xu¹, Slim Fourati¹, Ashish Sharma¹, Samuel Li¹, **Yogen Sauntharajah**², **Jaroslav Maciejewski**², **Thomas LaFramboise**¹, **Jill Barnholtz-Sloan**¹, **Rafick-Pierre Sekaly**¹, **David Wald**¹. ¹Case Western Reserve Univ., Cleveland, OH; ²Cleveland Clinic Foundation, Cleveland, OH

Session PO.BSB01.01. Applications of Cancer Computational Biology 1

April 2, 2019, 8:00 AM – 12:00 PM; Section 31

<https://www.abstractsonline.com/pp8/#!/6812/presentation/6046>

3557 / 13 - miR-181a is a key driver of genomic instability and ovarian cancer tumorigenesis through the regulation of RB1

Matthew Knarr¹, Lily Kwiatkowski¹, Anil Nagaraj¹, Ronny Drapkin², Analisa DiFeo³. ¹Case Western Reserve University, Cleveland, OH; ²University of Pennsylvania, Philadelphia, PA; ³University of Michigan, Ann Arbor, MI

Session PO.MCB10.04. miRNAs as Tumor Suppressors/Oncogenes

April 2, 2019, 8:00 AM – 12:00 PM; Section 37

<https://www.abstractsonline.com/pp8/#!/6812/presentation/7124>

3559 / 15 - A crowd-control approach for castration-resistant prostate cancer therapeutics

Girish C. Shukla. Cleveland State Univ., Cleveland, OH

Session PO.MCB10.04. miRNAs as Tumor Suppressors/Oncogenes

April 2, 2019, 8:00 AM – 12:00 PM; Section 37

<https://www.abstractsonline.com/pp8/#!/6812/presentation/7126>

3576 / 11 - MALAT1 is essential for A-NHEJ pathway choice during B cell immunoglobulin class switch recombination

Jianjun Zhao, Yi Hu, Jianhong Lin, Hua Fang. **Cleveland Clinic Lerner Research Institute, Cleveland, OH**

Session PO.MCB10.06. Noncoding RNAs 2

April 2, 2019, 8:00 AM – 12:00 PM; Section 38

<https://www.abstractsonline.com/pp8/#!/6812/presentation/7207>

CT220 / 14 - Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer

Kate Smith¹, Jorge M. Ferrer¹, Barbara L. Smith², E. Shelley Hwang³, Kelly K. Hunt⁴, Daleela G. Dodge⁵, Stephen E. Karp⁶, Stephanie A. Valente⁷, Irene L. Wapnir⁸, Lynne P. Clark⁹, David R. Carr¹⁰, Peter D. Beitsch¹¹, Donna L. Dyess¹², Beth-Ann Lesnikoski¹³, Peter W. Blumencranz¹⁴, Nayana S. Dekhne¹⁵, Linsey P. Gold¹⁶, Anees Chagpar¹⁷, Katherine Kacena¹, Livia Gjylameti¹, Felix Geissler¹. ¹Lumicell, Inc., Newton, MA; ²Massachusetts General Hospital, Boston, MA; ³Duke University, Durham, NC; ⁴The University of Texas MD Anderson Cancer Center, Houston, TX; ⁵Penn State Health Milton S. Hershey Medical Center,

Hershey, PA; ⁶Lahey Hospital and Medical Center, Burlington, MA; ⁷**Cleveland Clinic Health System, Cleveland, OH**; ⁸Stanford University School of Medicine, Stanford, CA; ⁹Franciscan Breast Surgical Associates- St. Joseph's Medical Center, Tacoma, WA; ¹⁰Novant Health Salem Surgical Associates, Winston-Salem, NC; ¹¹Dallas Surgical Group, Dallas, TX; ¹²University of South Alabama Surgical Specialists, Mobile, AL; ¹³Baptist MD Anderson Cancer Center, Jacksonville, FL; ¹⁴The Comprehensive Breast Care Center of Tampa Bay, Clearwater, FL; ¹⁵Beaumont Health, Royal Oak, MI; ¹⁶Comprehensive Breast Care, Troy, MI; ¹⁷Yale New Haven Hospital, New Haven, CT

Session PO.CT08. Phase I-III Trials in Progress: Part 3

April 2, 2019, 1:00 PM – 5:00 PM; Section 17

<https://www.abstractsonline.com/pp8/#!/6812/presentation/10033>

4013 / 6 - CoA Synthase (COASY): A novel predictive marker and functional protein that mediates radiation resistance via PI3K signaling in rectal cancer

Sylvain Ferrandon, Jennifer DeVecchio, Leonardo Duares, Hanuman Chouhan, Jacqueline Davenport, Georgios Karagkounis, Matthew Orloff, David Liska, **Matthew F. Kalady. Cleveland Clinic, Cleveland, OH**

Session PO.CL11.10. Tumor Markers to Assess the Biology and Clinical Course of Cancer 2

April 2, 2019, 1:00 PM – 5:00 PM; Section 21

<https://www.abstractsonline.com/pp8/#!/6812/presentation/5042>

4043 / 6 - Application of high complexity flow cytometry for Monitoring activated T-cells, T and B regulatory subsets in combination immunotherapy trials, melanoma case study

Jennifer Tsau¹, Michael Abadier¹, Brittney Atzmiller¹, Christine Vaupel¹, Naveen Dakappagari¹, Ghanashyam Sarikonda¹, **Ahmad Tarhini²**. ¹Navigate BioPharma Services, Inc., a Novartis subsidiary, Carlsbad, CA; ²**Cleveland Clinic, Cleveland, OH**

Session PO.IM02.09. Biomarkers and Immune Monitoring

April 2, 2019, 1:00 PM – 5:00 PM; Section 22

<https://www.abstractsonline.com/pp8/#!/6812/presentation/3227>

4062 / 25 – Activation of innate and adaptive immunity using intratumoral tilsotolimod (IMO-2125) as monotherapy in patients with refractory solid tumors: a phase Ib study (ILLUMINATE-101)

Hani M. Babiker¹, Vivek Subbiah², Orla Maguire³, Shah Rahimian⁴, Hans Minderman³, Cara L. Haymaker², Chantale Bernatchez², Erkut Borazanci⁵, James Geib⁴, Srinivas K. Chunduru⁴, **Peter M. Anderson⁶**, Igor Puzanov³, Adi Diab². ¹University of Arizona Cancer Center, Tucson, AZ; ²University of Texas MD Anderson Cancer Center, Houston, TX; ³Roswell Park Comprehensive Cancer Center, Buffalo, NY; ⁴Idera Pharmaceuticals, Exton, PA; ⁵HonorHealth Research Institute, Scottsdale, AZ; ⁶**Cleveland Clinic, Cleveland, OH**

Session PO.IM02.09. Biomarkers and Immune Monitoring

April 2, 2019, 1:00 PM – 5:00 PM; Section 22

<https://www.abstractsonline.com/pp8/#!/6812/presentation/3738>

4173 / 18 - Previously identified common glioma risk SNPs are associated with familial glioma

Quinn T. Ostrom¹, Georgina Armstrong¹, Christopher I. Amos¹, Jonine L. Bernstein², Elizabeth B. Claus³, Jeanette E. Eckel-Passow⁴, Dora Il'yasova⁵, Christoffer Johansen⁶, Daniel H. Lachance⁴, Rose K. Lai⁷, Ryan T. Merrell⁸, Sara H. Olson⁹, Joellen H. Schildkraut¹⁰, Sanjay S. Shete¹¹, Richard S. Houlston¹², Robert B. Jenkins⁴, Margaret R. Wrensch¹³, Beatrice Melin¹⁴, **Jill S. Barnholtz-Sloan¹⁵**, Melissa L. Bondy¹. ¹Baylor College of Medicine, Houston, TX; ²Memorial Sloan Kettering Cancer Center, Houston, NY; ³Yale University, New Haven, CT; ⁴Mayo Clinic College of Medicine, Rochester, MN; ⁵Georgia State University, Atlanta, GA; ⁶The Danish Cancer Society Research Center, Copenhagen, Denmark; ⁷University of

Southern California, Los Angeles, CA; ⁸NorthShore University Health System, Evanston, IL; ⁹Memorial Sloan Kettering Cancer Center, New York, NY; ¹⁰University of Virginia School of Medicine, Charlottesville, VA; ¹¹University of Texas MD Anderson Cancer Center, Houston, TX; ¹²The Institute of Cancer Research, Surrey, United Kingdom; ¹³University of California, San Francisco, San Francisco, CA; ¹⁴Umeå University, Umeå, Sweden; ¹⁵**Case Western Reserve University School of Medicine, Cleveland, OH**

Session PO.EP01.07 - Cancer Predisposition

April 2, 2019, 1:00 PM - 5:00 PM; Section 26

<https://www.abstractsonline.com/pp8/#!/6812/presentation/1916>

4347 / 7 - Differentially expressed genes and molecular pathways in an autochthonous mouse prostate cancer model

Shiv Verma, **Sanjeev Shukla**, Mitali Pandey, **Gregory T. MacLennan**, **Sanjay Gupta**. **Case Western Reserve Univ., Cleveland, OH**

Session PO.MCB09.02. Functional Genomics

April 2, 2019, 1:00 PM – 5:00 PM; Section 34

<https://www.abstractsonline.com/pp8/#!/6812/presentation/3402>

4395 / 13 - The cMYC-associated transcription factor JPO2 is upregulated in taxane resistant prostate cancer cells and interacts with the stress oncoprotein LEDGF/p75

Greisha L. Ortiz Hernandez¹, Shannalee Martinez¹, Evelyn Sanchez-Hernandez¹, Leslimar Rios-Colon², Christina Cajigas-DuRoss³, Tino Sanchez¹, Nouri Neamati⁴, Carlos A. Casiano¹. ¹Loma Linda University, Loma Linda, CA; ²North Carolina Central University, Durham, NC; ³**Cleveland Clinic, Cleveland, OH**; ⁴University of Michigan, Ann Arbor, MI

Session PO.MCB04.03. Post-transcriptional and Translational Control of Gene Regulation

April 2, 2019, 1:00 PM – 5:00 PM; Section 36

<https://www.abstractsonline.com/pp8/#!/6812/presentation/4738>

4746 / 7 - Identifying states of collateral sensitivity during the evolution of therapy resistance in Ewing's sarcoma

Erin McClure¹, Masahiro Hitomi¹, Jessica Scarborough², **Jacob Scott**¹. ¹**Cleveland Clinic, Cleveland, OH**; ²**Case Western Reserve University School of Medicine, Cleveland, OH**

Session PO.ET03.06. Drug Resistance 6

April 3, 2019, 8:00 AM – 12:00 PM; Section 11

<https://www.abstractsonline.com/pp8/#!/6812/presentation/1651>

5045 / 9 - Pineal gland volume and risk of prostate cancer

Latifa A. Bazzi¹, Lara Sigurdardottir², Sigurdur Sigurdsson³, Unnur Valdimarsdottir⁴, Johanna Torfadottir⁵, Thor Aspelund⁴, Lenore Launer⁶, Tamara Harris⁶, Vilmundur Gudnason³, Lorelei Mucci⁷, **Sarah Markt**⁸. ¹University of Michigan School of Public Health, Ann Arbor, MI; ²Icelandic Cancer Society, University of Iceland, Reykjavik, Iceland; ³Icelandic Heart Association, Reykjavik, Iceland; ⁴Icelandic Heart Association, University of Iceland, Reykjavik, Iceland; ⁵University of Iceland, Reykjavik, Iceland; ⁶National Institute on Aging, Bethesda, MD; ⁷Harvard T.H. Chan School of Public Health, Boston, MA; ⁸**Case Western Reserve University, Cleveland, OH**

Session PO.EP01.03 - Influences on Cancer Risk and Outcomes

April 3, 2019, 8:00 AM - 12:00 PM; Section 26

<https://www.abstractsonline.com/pp8/#!/6812/presentation/1895>

5084 / 22 - Epigenetic modifications involving reactivation of RECK inhibiting MMP-9 and MMP-2 in prostate cancer

Eswar Shankar, Omair Iqbal, Natarajan Bhaskaran, Gauri Deb, **Gregory T. MacLennan, Pingfu Fu, Sanjay Gupta. Case Western Reserve Univ., Cleveland, OH**

Session PO.PR01.02. Cancer Chemoprevention and Interception: From Mechanism to Translation

April 3, 2019, 8:00 AM – 12:00 PM; Section 27

<https://www.abstractsonline.com/pp8/#!/6812/presentation/1270>

5234 / 5 - Epigenetic control of heparanase expression through CRISPR/dCas9

Guihua Zeng¹, **Fu-Sen Liang²**, Lina Cui¹. ¹University of Florida, Gainesville, FL; ²**Case Western Reserve University, Cleveland, OH**

Session PO.MCB04.04 - Regulation of Gene Expression in Cancer

April 3, 2019, 8:00 AM - 12:00 PM; Section 37

<https://www.abstractsonline.com/pp8/#!/6812/presentation/4697>

Minisymposium

2685 - Identification of circulating protein biomarkers for colorectal cancer risk: A genetic instrument analysis

Xiang Shu¹, Xiao-ou Shu¹, Jirong Long¹, Qiuyin Cai¹, Conghui Qu², Stephanie L. Schmit³, Chenxu Qu⁴, Sonja I. Berndt⁵, Peter T. Campbell⁶, Andrew T. Chan⁷, Graham G. Giles⁸, Andrea Gsur⁹, Michael Hoffmeister¹⁰, Mark A. Jenkins¹¹, **Sanford D. Markowitz¹²**, Li Li¹³, Gad Rennert¹⁴, Kenneth Offit¹⁵, David Conti¹⁶, Annika Lindblom¹⁷, Graham Casey¹⁸, Stephen B. Gruber¹⁶, Ulrike Peters², Wei Zheng¹. ¹Vanderbilt University Medical Center, Nashville, TN; ²Fred Hutchinson Cancer Research Center, Seattle, WA; ³H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; ⁴USC Norris Comprehensive Cancer Center, Los Angeles, CA; ⁵National Cancer Institute, National Institutes of Health, Bethesda, MD; ⁶American Cancer Society, Atlanta, GA; ⁷Massachusetts General Hospital and Harvard Medical School, Boston, MA; ⁸Cancer Council Victoria, Melbourne, Australia; ⁹Institute of Cancer Research, Medical University Vienna, Vienna, Austria; ¹⁰German Cancer Research Center (DKFZ), Heidelberg, Germany; ¹¹Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia; ¹²**Case Comprehensive Cancer Center, Case Western Reserve University, and University Hospitals of Cleveland, Cleveland, OH**; ¹³**Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH**; ¹⁴Lady Davis Carmel Medical Center, Haifa, Israel; ¹⁵Memorial Sloan-Kettering Cancer Center, New York, NY; ¹⁶USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA; ¹⁷Karolinska University Hospital, Stockholm, Sweden; ¹⁸University of Virginia, Charlottesville, VA

Session MS.EP01.02 Exposures and Genetic in Cancer Risk

April 1, 2019, 4:20 PM – 4:35 PM; Room C302 – Georgia World CC

<https://www.abstractsonline.com/pp8/#!/6812/presentation/1516>

2711 - Rational combination of GITR agonism with PD-1 blockade
Roberta Zappasodi¹, Cynthia Sirard², Yanyun Li¹, Sadna Budhu¹, Moshen Abu-Akeel¹, Cailian Liu¹, Xia Yang¹, Hong Zhong¹, Walter Newman², Jingjing Qi¹, Philip Wong¹, David Schaer¹, **Henry Koon**³, Vamsidhar Velcheti⁴, Margaret K. Callahan¹, Jedd Wolchok¹, Taha Merghoub¹. ¹Mem. Sloan Kettering Cancer Ctr., New York, NY; ²Leap Therapeutics, Boston, MA; ³**Case Western Reserve University, Cleveland, OH**; ⁴**Cleveland Clinic, Cleveland, OH**

Session MS.IM02.01. Rational Combinations of Immunotherapy
April 1, 2019 4:05 PM – 4:20 PM; Room A411 – Georgia World CC
<https://www.abstractsonline.com/pp8/#!/6812/presentation/2234>

2745 - Tumor microenvironment and host genetics impact glioma progression in a Collaborative Cross-based orthotopic allograft model

Kasey Skinner¹, Martin Ferris¹, Ryan Bash¹, Abigail Shelton¹, Erin Smithberger¹, Steve Angus¹, Brian Golitz¹, Noah Sciaky¹, Jeremy Simon¹, Jason Stein¹, Glenn Matsushima¹, Quinn Ostrom², Lindsay Stetson³, **Jill Barnholtz-Sloan**³, Harshil Dhruv⁴, Michael Berens⁴, Fernando Pardo Manuel de Villena¹, C. Ryan Miller¹. ¹UNC Chapel Hill, Chapel Hill, NC; ²Baylor College of Medicine, Houston, TX; ³**Case Western Reserve University, Cleveland, OH**; ⁴Translational Genomics Research Institute, Phoenix, AZ

Session MS.TB06.02 - Signaling in the Tumor Microenvironment
April 1, 2019, 3:50 PM - 4:05 PM; Room A404 - Georgia World CC
<https://www.abstractsonline.com/pp8/#!/6812/presentation/4281>

4487 - Association of the tumor-immune microenvironment with response to niraparib and pembrolizumab in relapsed, platinum-resistant ovarian cancer

Anniina Farkkila¹, Jia R. Lin², Julia Casado¹, Huy Nguyen¹, Yinghui Zhou³, Julie R. Graham³, Bruce J. Dezube³, **Steven Waggoner**⁴, Pamela Munster⁵, Gini F. Fleming⁶, Sandro Santagata⁷, Ursula A. Matulonis¹, Peter K. Sorger², Elizabeth M. Swisher⁸, Alan D. D'Andrea¹, Panagiotis Konstantinopoulos¹. ¹Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ²Harvard Medical School and Ludwig Center for Cancer Research at Harvard, Boston, MA; ³Tesaro, Waltham, MA; ⁴**University Hospitals of Cleveland, Cleveland, OH**; ⁵Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; ⁶University of Chicago, Chicago, IL; ⁷Brigham and Women's Hospital, Laboratory for Systems Pharmacology, Boston, MA; ⁸University of Washington, Seattle, WA

Session MS.IM02.02 - Tumor Immune Microenvironment
April 2, 2019, 3:00 PM - 5:00 PM; Room A411 - Georgia World CC
<https://www.abstractsonline.com/pp8/#!/6812/presentation/2231>

Late-Breaking Poster Session

LB-082 / 2 - The Kindlin2-p53-SerpinB2 signaling axis is required for the regulation of cellular senescence in breast cancer

Khalid Sossey-Alaoui¹, Elzbieta Pluskota², Dorota Szpak², **Edward F. Plow**². ¹**Case Western Reserve University School of Medicine, Cleveland, OH**; ²**Cleveland Clinic Lerner Research Inst., Cleveland, OH**

Session LBPO.MCB01. Late-Breaking Research: Molecular and Cellular Biology/Genetics 1
April 1, 2019, 8:00 AM – 12:00 PM; Section 42
<https://www.abstractsonline.com/pp8/#!/6812/presentation/9240>

LB-117 / 12 - Increased peripheral glucose levels restores chemotherapeutic efficacy in a mouse model of pancreatic cancer

Ali Vaziri-Gohar¹, Imran Khokhar², George Titomihelakis², Jonathan R. Brody², **Jordan M. Winter³**. ¹**Case Western Reserve University, School of Medicine, Cleveland, OH**; ²Thomas Jefferson University, Department of Surgery, Philadelphia, PA; ³**University Hospitals Cleveland Medical Center and Case Western Reserve University, Division of Surgical Oncology, Cleveland, OH**

Session LBPO.ET01 Late-Breaking Research: Experimental and Molecular Therapeutics 1

April 1, 2019, 1:00 PM – 5:00 PM; Section 40

<https://www.abstractsonline.com/pp8/#!/6812/presentation/9155>

LB-294 / 11 - Targeting glutamine addiction of PIK3CA mutant colorectal cancers: From preclinical models to clinical trials

Yiqing Zhao¹, **Jennifer Eads²**, **David Bajor²**, **Zhenghe wang¹**. ¹**Case Western Reserve Univ., Cleveland, OH**; ²**University Hospitals Seidman Cancer Center, Cleveland, OH**

Session LBPO.MCB02. Late-Breaking Research: Molecular and Cellular Biology/Genetics 2

April 3, 2019, 8:00 AM – 12:00 PM; Section 41

<https://www.abstractsonline.com/pp8/#!/6812/presentation/9273>

LB-306 / 23 - Long non-coding RNA NEAT1 promotes lung metastasis of soft tissue sarcoma by regulating RNA splicing pathways

Jianguo Huang¹, Eric Xu¹, Mohit Sachdeva¹, Timothy Robinson¹, Xiaodi Qin¹, Dadong Zhang¹, Kouros Owzar¹, Nalan Gokgoz², Andrew Seto², Irene Andrulis², Jay Wunder², Tomoyo Okada³, Simuel Singer³, Alexander Lazar⁴, **Brian Rubin⁵**, David G. Kirsch¹. ¹Duke University Medical Center, Durham, NC; ²Samuel Lunenfeld Research Institute, Toronto, ON, Canada; ³Memorial Sloan-Kettering Cancer Center, New York, NY; ⁴MD Anderson Cancer Center, Houston, TX; ⁵**Cleveland Clinic, Cleveland, OH**

Session LBPO.MCB02 - Late-Breaking Research: Molecular and Cellular Biology / Genetics 2

April 3, 2019, 8:00 AM - 12:00 PM; Section 41

<https://www.abstractsonline.com/pp8/#!/6812/presentation/9285>

Travel Award

Yorlenny M. Vicioso, BS, Graduate Student, Case Western Reserve University School of Medicine, Cleveland, OH. Abstract 3186. A novel combination therapy for treating advanced drug resistant acute lymphoblastic leukemia